Trial Profile

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tesnatilimab (Primary) ; Ustekinumab
Indications Crohn's disease
Focus Proof of concept; Therapeutic Use
Acronyms TRIDENT
Sponsors Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag

27 Sep 2022 Results assessing population pharmacokinetic of Tesnatilimab in Moderately to Severely active Crohns Disease modeling presented at the 2022 American College of Clinical Pharmacology Annual Meeting
12 Apr 2022 Status changed from active, no longer recruiting to completed.
29 Sep 2020 Planned End Date changed from 1 Sep 2022 to 10 Sep 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com